- 1.
Khoury DS, Cromer D, Reynaldi A et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; 27: 1205–11. [PubMed][CrossRef]
- 2.
Goel RR, Painter MM, Apostolidis SA et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 2021; 374: abm0829. [PubMed][CrossRef]
- 3.
Chen Y, Klein SL, Garibaldi BT et al. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res Rev 2021; 65: 101205. [PubMed][CrossRef]
- 4.
Tartof SY, Slezak JM, Fischer H et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021; 398: 1407–16. [PubMed][CrossRef]
- 5.
UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf Lest 6.1.2022.
- 6.
UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 33. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1043807/technical-briefing-33.pdf Lest 14.2.2022.
- 7.
Hansen CH, Schelde AB, Moustsen-Helm IR et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. Preprint 22.12.2021. https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v2 Lest 14.2.2022.
- 8.
Haveri A, Solastie A, Ekström N et al. Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults. Preprint 24.12.2021. https://www.medrxiv.org/content/10.1101/2021.12.22.21268273v1 Lest 14.2.2022.
- 9.
Buchan SA, Chung H, Brown KA et al. Effectiveness of COVID-19 vaccines against Omicron or Delta infection. Preprint 1.1.2022. https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1 Lest 14.2.2022.
- 10.
Geers D, Shamier MC, Bogers S et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci Immunol 2021; 6: 1750. [PubMed][CrossRef]
- 11.
Redd AD, Nardin A, Kared H et al. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals. Preprint 9.12.2021. https://www.biorxiv.org/content/10.1101/2021.12.06.471446v1 Lest 14.2.2022.
- 12.
Chen X, Rostad CA, Anderson LJ et al. The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein. Virology 2021; 559: 1–9. [PubMed][CrossRef]
- 13.
Folkehelseinstituttet. COVID-19. Ukerapport – uke 3, onsdag 26. januar 2022. https://www.fhi.no/contentassets/8a971e7b0a3c4a06bdbf381ab52e6157/vedlegg/2022/ukerapport-uke-3-17.01---23.01.22.pdf Lest 14.2.2022.
- 14.
Barda N, Dagan N, Cohen C et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021; 398: 2093–100. [PubMed][CrossRef]
- 15.
Arbel R, Hammerman A, Sergienko R et al. BNT162b2 Vaccine Booster and Mortality Due to Covid-19. N Engl J Med 2021; 385: 2413–20. [PubMed][CrossRef]
- 16.
Falsey AR, Frenck RW, Walsh EE et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med 2021; 385: 1627–9. [PubMed][CrossRef]
- 17.
Munro APS, Janani L, Cornelius V et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021; 398: 2258–76. [PubMed][CrossRef]
- 18.
Planas D, Saunders N, Maes P et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 2021; 600. doi: 10.1038/s41586-021-04389-z. [PubMed][CrossRef]
()